The prevalence of multiple sclerosis in the United States has steadily grown over the past 5 years to nearly 1 million people.
Erica Slaughter, MS
Advertisement
Articles by Erica Slaughter, MS
Nonmyeloablative hematopoietic stem cell transplant found to prolong time to multiple sclerosis disease progression compared with disease-modifying therapies.
Ocrelizumab found more effective in reducing the risk of 12-week confirmed disability progression compared with 10 other treatments for relapsing multiple sclerosis.
Advertisement
Latest Updated Articles
Ocrelizumab Superior or Comparable to Other Disease-Modifying MS DrugsPublished: January 17th 2019 | Updated:
Stem Cell Transplantation Shows Greater Benefits for Relapsing-Remitting MSPublished: January 24th 2019 | Updated:
Study Shows Steady Rise of Multiple Sclerosis Prevalence in United StatesPublished: March 7th 2019 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Recognizing Immunizing Pharmacists in the Community
2
FDA, HHS Move to Accelerate Biosimilar Approvals
3
Denosumab Biosimilars Conexxence and Bomyntra Receive Interchangeability Designation
4
Accelerated Approval of Cancer Drugs: Benefit or Burden?
5
